. 2014 May 28;20(20):6262–6278. doi: 10.3748/wjg.v20.i20.6262

Table 3.

National Institute for Health and Care Excellence treatment guidelines

Guidelines	HBeAg positive	HBeAg negative	Decompensated
1^st line	48-wk of PEG-IFN-α-2a	48-wk of PEG-IFN-α-2a	ETV or TDF (LAM resistance)
2^nd line	TDF or ETV (TDF contraindication)	ETV or TDF
3^rd line	LAM + TDFor ETV + TDF (LAM resistance)	ETV or TDF

In adults with compensated liver disease, current guidelines advise first-line treatment with 48 wk of PEG-IFN-α-2a. If PEG-IFN-α-2a is contraindicated, tenofovir or entecavir should be trialed. PEG-IFN: Pegylated interferon; HBeAg: Hepatitis B e antigen; ETV: Entecavir; LAM: Lamivudine; TDF: Tenofovir disoproxil fumarate.